Vaccines

Celldex initiates pivotal glioblastoma study with EGF-R vaccine

Celldex Therapeutics has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the ¡°ACT IV Study.¡± Rindopepimut is a therapeutic cancer vaccine candidate that targets the tumor-specific oncogene EGFRvIII, which confers an enhanced capacity for unregulated tumor growth and which is present in many cancer cell types, but not present at significant levels in normal cells. Expression of EGFRvIII is linked to poor long term survival regardless of other factors such as extent of resection and age. EGFRvIII has been shown by polymerase chain reaction (PCR) analysis to be expressed in approximately 31% of glioblastoma tumors.
Read more ?
http://www.pipelinereview.com/index.php/2011120146453/Vaccines/Celldex-Initiates-ACT-IV-a-Pivotal-International-Phase-3-Trial-of-Rindopepimut-in-Patients-with-Glioblastoma.html

Volume 4, Issue 48 December 5, 2011
Page 5